AI-generated summary
The authors examined Brazilian court databases, including state courts and the two higher courts, to identify legal routes by which patients obtained photobiomodulation therapy for oral mucositis during cancer care. Of 50 eligible rulings from 2005 to 2024, 82% were fully granted and 18% partially granted, with most directed at health insurance providers. The authors describe this as a consistent legal framework supporting access.
- Who or what was studied
- Court rulings concerning access to photobiomodulation therapy for oral mucositis in Brazilian cancer care
- Limits stated in the abstract
- The study is retrospective and cross-sectional and analyzes court rulings rather than patients, so it cannot assess clinical outcomes.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation therapy, Photobiomodulation, Oral mucositis. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.